相似文献
1
Hepatitis C Virus Is Associated With Increased Mortality Among Incarcerated Hospitalized Persons in Massachusetts.丙型肝炎病毒与马萨诸塞州住院囚犯的死亡率增加有关。
Open Forum Infect Dis. 2021 Dec 18;8(12):ofab579. doi: 10.1093/ofid/ofab579. eCollection 2021 Dec.
2
Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019.伊朗在押人员中乙型肝炎和丙型肝炎感染的患病率：2019年全国性横断面生物行为研究
Pathogens. 2021 Nov 21;10(11):1522. doi: 10.3390/pathogens10111522.
3
Prevalence of infection with hepatitis B and C viruses and co-infection with HIV in three jails: a case for viral hepatitis prevention in jails in the United States.三座监狱中乙型和丙型肝炎病毒感染率及与艾滋病毒的合并感染情况：美国监狱中病毒性肝炎预防的一个实例
J Urban Health. 2009 Jan;86(1):93-105. doi: 10.1007/s11524-008-9305-8. Epub 2008 Jul 12.
4
Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination.五个关于司法系统中丙型肝炎管理的问题：为丙型肝炎病毒消除寻找切实可行的解决方案。
Infect Dis Clin North Am. 2018 Jun;32(2):323-345. doi: 10.1016/j.idc.2018.02.014.
5
Addressing Hepatitis C in the American Incarcerated Population: Strategies for Nationwide Elimination.解决美国监禁人群中的丙型肝炎问题：实现全国消除的策略。
Curr HIV/AIDS Rep. 2020 Feb;17(1):18-25. doi: 10.1007/s11904-019-00476-z.
6
High Prevalence of Hepatitis C Infection Among Adult Patients at Four Urban Emergency Departments - Birmingham, Oakland, Baltimore, and Boston, 2015-2017.2015-2017 年，四个城市急诊部成年患者中丙型肝炎感染的高流行率-伯明翰、奥克兰、巴尔的摩和波士顿。
MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):569-574. doi: 10.15585/mmwr.mm6919a1.
7
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.澳大利亚监狱内丙型肝炎治疗即预防的评估（SToP-C）：一项前瞻性队列研究。
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):533-546. doi: 10.1016/S2468-1253(21)00077-7. Epub 2021 May 7.
8
HIPPOCRATES project: A proof of concept of a collaborative program for hepatitis C virus micro-elimination in a prison setting.希波克拉底项目：监狱环境中丙型肝炎病毒微消除合作项目的概念验证
World J Hepatol. 2020 Dec 27;12(12):1314-1325. doi: 10.4254/wjh.v12.i12.1314.
9
Understanding facilitators and barriers of direct-acting antiviral therapy for hepatitis C virus infection in prison.了解监狱中丙型肝炎病毒感染直接作用抗病毒治疗的促进因素和障碍。
J Viral Hepat. 2018 Dec;25(12):1526-1532. doi: 10.1111/jvh.12987. Epub 2018 Sep 19.
10
Incidence and correlates of hepatitis C virus infection in a large cohort of prisoners who have injected drugs.一大群注射毒品囚犯中丙型肝炎病毒感染的发病率及其相关因素。
BMC Public Health. 2014 Aug 11;14:830. doi: 10.1186/1471-2458-14-830.
引用本文的文献
1
Hepatitis C Testing Protocols Across Massachusetts Jails, 2022-2023: An Opportunity for Intervention.2022 - 2023年马萨诸塞州各监狱的丙型肝炎检测方案：干预的契机
Public Health Rep. 2025 Jun 16:333549251325067. doi: 10.1177/00333549251325067.
2
Linkages between incarceration and health for older adults.老年人监禁与健康之间的联系。
Health Justice. 2025 Apr 17;13(1):23. doi: 10.1186/s40352-025-00331-x.
3
The Impact of Incarceration on Readmissions Among Patients With Inflammatory Bowel Disease Hospitalized at a Community Hospital.监禁对在社区医院住院的炎症性肠病患者再入院率的影响。
Gastro Hep Adv. 2023 Mar 16;2(5):660-665. doi: 10.1016/j.gastha.2023.03.016. eCollection 2023.
4
Advancing Hepatitis C Elimination through Opt-Out Universal Screening and Treatment in Carceral Settings, United States.通过在监禁场所实施默认普遍筛查和治疗来推进丙型肝炎消除工作，美国。
Emerg Infect Dis. 2024 Apr;30(13):S80-S87. doi: 10.3201/eid3013.230859.
本文引用的文献
1
"I'm not gonna be able to do anything about it, then what's the point?": A broad group of stakeholders identify barriers and facilitators to HCV testing in a Massachusetts jail.“如果我对此无能为力，那又有什么意义呢？”：马萨诸塞州监狱内广泛的利益相关者群体确定了丙型肝炎病毒检测的障碍和促进因素。
PLoS One. 2021 May 26;16(5):e0250901. doi: 10.1371/journal.pone.0250901. eCollection 2021.
2
Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care.纽约市监狱人群中丙型肝炎病毒治疗的结果：扩大护理规模面临的成功与挑战
Open Forum Infect Dis. 2020 Jun 30;7(7):ofaa263. doi: 10.1093/ofid/ofaa263. eCollection 2020 Jul.
3
Association of Direct-Acting Antiviral Treatment With Mortality Among Medicare Beneficiaries With Hepatitis C.直接作用抗病毒治疗与医疗保险受益人群丙型肝炎死亡率的关联。
JAMA Netw Open. 2020 Jul 1;3(7):e2011055. doi: 10.1001/jamanetworkopen.2020.11055.
4
Characteristics Associated with Hospitalization Among Patients with COVID-19 - Metropolitan Atlanta, Georgia, March-April 2020.与 COVID-19 患者住院相关的特征- 2020 年 3 月至 4 月，佐治亚州亚特兰大都会区。
MMWR Morb Mortal Wkly Rep. 2020 Jun 26;69(25):790-794. doi: 10.15585/mmwr.mm6925e1.
5
Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017.2014-2017 年，有先进肝病治疗途径的丙型肝炎患者对直接作用抗病毒治疗的接受率低。
J Clin Gastroenterol. 2021 Jan;55(1):77-83. doi: 10.1097/MCG.0000000000001344.
6
The Burden of Untreated HCV Infection in Hospitalized Inmates: a Hospital Utilization and Cost Analysis.未治疗 HCV 感染在住院囚犯中的负担：医院利用和成本分析。
J Urban Health. 2018 Aug;95(4):467-473. doi: 10.1007/s11524-018-0277-z.
7
Racial disparities in health conditions among prisoners compared with the general population.与普通人群相比，囚犯健康状况中的种族差异。
SSM Popul Health. 2017 Dec;3:487-496. doi: 10.1016/j.ssmph.2017.05.011.
8
Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的 HCV 患者的肝细胞癌风险。
Gastroenterology. 2017 Oct;153(4):996-1005.e1. doi: 10.1053/j.gastro.2017.06.012. Epub 2017 Jun 19.
9
New Hepatitis C Drugs Are Very Costly And Unavailable To Many State Prisoners.新型丙型肝炎药物价格高昂，许多州立监狱的囚犯无法获得。
Health Aff (Millwood). 2016 Oct 1;35(10):1893-1901. doi: 10.1377/hlthaff.2016.0296.
10
Reversion of disease manifestations after HCV eradication.HCV 清除后疾病表现的逆转。
J Hepatol. 2016 Oct;65(1 Suppl):S95-S108. doi: 10.1016/j.jhep.2016.07.039.
Zotero 插件